Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Rao

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Current Opinion in Pulmonary Medicine|March 19, 2016
Host-directed therapies for antimicrobial resistant respiratory tract infectionsMarkus Maeurer, Martin Rao, Alimuddin Zumla
Annals of Translational Medicine|June 6, 2015
Host directed therapies (HDTs) and immune response signatures: insights into a role for interleukin-32Markus Maeurer, Martin Rao, Alimuddin Zumla
The Lancet. Respiratory Medicine|March 30, 2018
B cells or T cells in TB: a continuing conundrumMarkus Maeurer, Martin Rao, Alimuddin Zumla
Current Opinion in Pulmonary Medicine|March 19, 2019
Precision medicine in the clinical management of respiratory tract infections including multidrug-resistant tuberculosis: learning from innovations in immuno-oncologyMartin Rao, Dario Ligeiro, Markus Maeurer
The Lancet. Respiratory Medicine|March 2, 2015
Host-directed therapy: tuberculosis vaccine developmentMartin Rao, Alimuddin Zumla, Markus Maeurer
Frontiers in Microbiology|May 29, 2019
Immunometabolism and Pulmonary Infections: Implications for Protective Immune Responses and Host-Directed TherapiesMartin Rao, Ernest Dodoo, Alimuddin Zumla, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 5, 2018
Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosisMartin Rao, Davide Valentini, Alimuddin Zumla, et al.
BMC Medicine|June 16, 2016
Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosisAlimuddin Zumla, Martin Rao, Ernest Dodoo, et al.
Frontiers in Oncology|October 5, 2018
KRAS RENAISSANCE(S) in Tumor Infiltrating B Cells in Pancreatic CancerQingda Meng, Davide Valentini, Martin Rao, et al.
Scientific Reports|November 22, 2018
CMV and EBV targets recognized by tumor-infiltrating B lymphocytes in pancreatic cancer and brain tumorsQingda Meng, Davide Valentini, Martin Rao, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Current Opinion in Pulmonary Medicine|March 19, 2016
Host-directed therapies for antimicrobial resistant respiratory tract infectionsMarkus Maeurer, Martin Rao, Alimuddin Zumla
Annals of Translational Medicine|June 6, 2015
Host directed therapies (HDTs) and immune response signatures: insights into a role for interleukin-32Markus Maeurer, Martin Rao, Alimuddin Zumla
The Lancet. Respiratory Medicine|March 30, 2018
B cells or T cells in TB: a continuing conundrumMarkus Maeurer, Martin Rao, Alimuddin Zumla
Current Opinion in Pulmonary Medicine|March 19, 2019
Precision medicine in the clinical management of respiratory tract infections including multidrug-resistant tuberculosis: learning from innovations in immuno-oncologyMartin Rao, Dario Ligeiro, Markus Maeurer
The Lancet. Respiratory Medicine|March 2, 2015
Host-directed therapy: tuberculosis vaccine developmentMartin Rao, Alimuddin Zumla, Markus Maeurer
Frontiers in Microbiology|May 29, 2019
Immunometabolism and Pulmonary Infections: Implications for Protective Immune Responses and Host-Directed TherapiesMartin Rao, Ernest Dodoo, Alimuddin Zumla, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 5, 2018
Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosisMartin Rao, Davide Valentini, Alimuddin Zumla, et al.
BMC Medicine|June 16, 2016
Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosisAlimuddin Zumla, Martin Rao, Ernest Dodoo, et al.
Frontiers in Oncology|October 5, 2018
KRAS RENAISSANCE(S) in Tumor Infiltrating B Cells in Pancreatic CancerQingda Meng, Davide Valentini, Martin Rao, et al.
Scientific Reports|November 22, 2018
CMV and EBV targets recognized by tumor-infiltrating B lymphocytes in pancreatic cancer and brain tumorsQingda Meng, Davide Valentini, Martin Rao, et al.
Pageof 6